Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer

BACKGROUND: Only a fraction of patients with advanced non-small cell lung cancer (NSCLC) respond well to immune checkpoint blockade (ICB) therapy. Here, we investigated whether Titin (TTN) mutation, which has been demonstrated to be a predictive biomarker in tissue-based analysis, can identify patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Transl Lung Cancer Res
Asıl Yazarlar: Su, Chunxia, Wang, Xinxin, Zhou, Juan, Zhao, Jing, Zhou, Fei, Zhao, Guodong, Xu, Xiaohong, Zou, Xuan, Zhu, Bo, Jia, Qingzhu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2021
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8044474/
https://ncbi.nlm.nih.gov/pubmed/33889507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-1118
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller